Hannah Brendan
- SEC CIK
- 0001929422
No open-market purchases or sales filed in the past year.
Current role at each company
- QNCX Quince Therapeutics, Inc.CBO, COO & CCOas of Jan 23, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Hannah Brendan as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 21, 2024 (view filing) | Aug 19-21 | 2 days | Hannah BrendanCHIEF BUSINESS OFFICER AND COO | PPurchase | +38.9K | $0.6209 | +$24.2K | +15.1%296.5K after | 6 lots |
| Aug 9, 2023 (view filing) | Aug 8 | 1 day | Hannah BrendanChief Business Officer | PPurchase | +71.8K | $1.22 | +$87.5K | +55.3%201.6K after |